InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
2
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the detailed record of transactions filed by Ling Karen, 董事. Officer active across 4 companies, notably TherapeuticsMD, Inc.. In total, 17 reports have been logged. Breakdown: 2 buys · 0 sell. Total volume traded: €82k. History available since 17 August 2021. The latest transaction was disclosed on 26 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Ling Karen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报17 总计
15,842 股@ US$15.780.0037% mcap100.0% 占其流量Common Shares, No Par ValueSEC:0001860742-26-000078:0
4,000 股@ US$17.74221.9% 占其流量Common Shares, No Par ValueSEC:0001860742-26-000020:0
标准退出：2026年5月20日 (T+90)
1,358 股0Common StockSEC:0001388658-25-000129:0
20,338 股0Common Shares, No Par ValueSEC:0001127602-25-015803:0
14,696 股0Common Shares, No Par ValueSEC:0001127602-24-021757:0
1,841 股0Common StockSEC:0001388658-24-000122:0
2,642 股0Common Shares, No Par ValueSEC:0001127602-24-009005:0
23,122 股0Ordinary SharesSEC:0001104659-23-119109:0
1,396 股0Common StockSEC:0001388658-23-000128:0
3,154 股@ US$1.28100.0% 占其流量Ordinary SharesSEC:0001104659-23-076469:0
1,164 股0Common StockSEC:0001388658-23-000054:0
26,277 股0Ordinary SharesSEC:0001104659-23-001542:0
1,984 股Common StockSEC:0001209191-22-046965:0
653 股0Common StockSEC:0001388658-22-000072:0
4,320 股0Common StockSEC:0001388658-21-000147:0
33,445 股@ US$0.75100.0% 占其流量Common StockSEC:0001387131-21-008750:0
标准退出：2021年11月15日 (T+90)
96,864 股Common StockSEC:0001387131-21-008433:0
17 条申报中的 17 条
About Ling Karen
Ling Karen is Administrateur and is linked to iRhythm Technologies, Inc., Bausch & Lomb Corp, Mallinckrodt plc and TherapeuticsMD, Inc. She has 17 filings in total, and across the 17 sampled filings from 2021-08-12 to 2026-05-28, reported purchases total 81621 EUR, reported sales total 0 EUR, with the dominant transaction nature shown as Attribution.
